Showing 8311-8320 of 9740 results for "".
- Galderma's New #BreakTheIce Campaign Debunks the Fear of Frozen Lookhttps://practicaldermatology.com/news/galdermas-new-breaktheice-campaign-debunks-the-fear-of-frozen-look/2458612/When it comes to facial rejuvenation, fresh is the new frozen. Fully 74 percent of women and men aged 30-50 would be more interested in anti-aging treatments if results looked natural, according to new survey commissioned by Galderma Laborator
- Acella Pharmaceuticals Appoints New CEOhttps://practicaldermatology.com/news/acella-pharmaceuticals-appoints-new-ceo/2458613/Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, announced the appointment of Harold. A Deas, Jr. as Chief Executive Officer. Mr. Deas, who will retain his role as Chief Operating Officer, has been instrumental in helping Acella build a successful portfolio of generic and sp
- Kourtney Kardashian is Manuka Doctor's New Brand Ambassadorhttps://practicaldermatology.com/news/kourtney-kardashian-is-manuka-doctors-new-brand-ambassador/2458614/Kybella has Khloe, and now Manuka Doctors got Kourtney. Kourtney Kardashian is the new face of Manuka Doctor, a skincare line comprising Manuka Honey and patented Purified Bee Venom.
- American Telemedicine Association Names New Vice Chair of Teledermatologyhttps://practicaldermatology.com/news/american-telemedicine-association-names-new-vice-chair-of-teledermatology/2458616/Mark P. Seraly, MD, founder and chief medical officer of Iagnosis, a developer of telemedicine solutions and the creator of DermatologistOnCall, has been elected Vice Chair of the Teledermatology Special Interest Group of the American Telemedicine Association (ATA) the leading international resou
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Tissue Regeneration Leader Takes Home 2016 Furumoto Award at ASLMS 2016https://practicaldermatology.com/news/tissue-regeneration-leader-takes-home-2016-furumoto-award-at-aslms-2016/2458627/Praveen Arany, DDS, PhD will receive the 2016 ASLMS Dr. Horace Furumoto Innovations Young Investigator Award during the Plenary Session at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS).
- More Than 1,000 Patients Join Corrona Psoriasis Registryhttps://practicaldermatology.com/news/more-than-1000-patients-join-corrona-psoriasis-registry/2458631/The Corrona Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, now includes more than 1,000 patients from 100 sites. Dermatologists assess registry pa
- Profounda Launches Impavido for Visceral, Mucosal and Cutaneous Leishmaniasishttps://practicaldermatology.com/news/profounda-launches-impavido-for-visceral-mucosal-and-cutaneous-leishmaniasis/2458636/Profounda, Inc. launched Impavido (miltefosine) in the United States. Impavido is the first oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the FDA and the first Rx product launched in the US by Profounda. Although skin sores of cutaneous leishmaniasis (CL) us
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via